Chester Robachinski
Psychiatry · Seattle, WANPI 1285697573
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $842,185 of the $1,131,106 with a category attached, or 74.5%. 22 manufacturers reported payments, led by Johnson & Johnson at 37.8% of the total. 2025 is the largest year on record at $271,758, 2.3 times the $118,878 reported in 2019. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,856 payments — averaging $609.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$428K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224K
- AbbVie$128K
- Alkermes, Inc.$96K
- Vanda Pharmaceuticals Inc.$91K
- Axsome Therapeutics, Inc.$75K
- plus $89K from 16 others
What the payments were for
- Consulting fees$112,02910%
- Speaking & faculty fees$842,18574%
- Travel & lodging$139,80912%
- Food & beverage$37,0313%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 618 | $427,966 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 306 | $223,565 |
| AbbVie(2 entities) | 304 | $127,699 |
| Alkermes, Inc. | 176 | $96,314 |
| Vanda Pharmaceuticals Inc. | 130 | $90,999 |
| Axsome Therapeutics, Inc. | 100 | $75,318 |
| Neurocrine Biosciences, Inc. | 74 | $34,079 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 37 | $19,231 |
| Janssen Scientific Affairs, LLC | 18 | $19,199 |
| Sunovion Pharmaceuticals Inc. | 29 | $5,728 |
| Otsuka America Pharmaceutical, Inc. | 27 | $5,073 |
| Eisai Inc. | 13 | $4,901 |
| Jazz Pharmaceuticals Inc. | 8 | $379 |
| Tris Pharma Inc | 3 | $226 |
| Corium, LLC | 3 | $130 |
| Gilead | 1 | $113 |
| Viiv Healthcare Company | 2 | $52 |
| Lundbeck LLC | 2 | $39 |
| Shire North American Group Inc | 2 | $37 |
| Sage Therapeutics, LLC | 1 | $24 |
| Biogen | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$438,445
- CAPLYTA$218,417
- LYBALVI$198,264
- ARISTADA$183,217
- VRAYLAR$122,698
- Fanapt$89,784
- Auvelity$73,353
- ARISTADA INITIO$36,003
- INGREZZA$32,804
- Dayvigo$4,860
- LATUDA$4,334
- INVEGA SUSTENNA$3,633
- Ponvory$3,533
- REXULTI$253
- SUNOSI$249
- VIIBRYD$200
- INVEGA TRINZA$128
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Onyda XR$123
How this compares
$1,131,106 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 48 | $71,869 |
| CaplytaLumateperone Tosylate | 12 | $18,396 |
| Lurasidone Hcl | 36 | $6,260 |
| Atomoxetine Hcl | 27 | $1,236 |
| Bupropion XlBupropion Hcl | 58 | $1,142 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $1,027 |
| Trazodone Hcl | 75 | $1,012 |
| Olanzapine | 35 | $907 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $699 |
| Fluoxetine Hcl | 34 | $567 |
| Bupropion Hcl SrBupropion Hcl | 13 | $552 |
| Clonazepam | 48 | $536 |
| Quetiapine Fumarate | 16 | $509 |
| Mirtazapine | 25 | $439 |
| Duloxetine Hcl | 16 | $435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $127,699 | $71,86948 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $223,565 | $18,39612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Seattle
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Lina FineSeattle$30K
- Jonathan BuchholzSeattle$7K
- Steven MitchellSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Gerard ZanolliSeattle$3K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.